Aclovate (alclometasone topical) dosing, indications, interactions, adverse effects, and more.

Sections

Sections alclometasone topical
Dosing & Uses
Adverse Effects
Warnings
Pregnancy
Pharmacology
Images
Patient Handout
Formulary

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

cream

0.05%

ointment

0.05%

Inflammatory & Pruritic Skin Disorders

Apply thin film to affected area q8-12hr; discontinue treatment when control achieved

Reassess diagnosis if no improvement within 2 weeks

Dosage Forms & Strengths

cream

0.05%

ointment

0.05%

Inflammatory & Pruritic Skin Disorders

Apply thin film to affected area q8-12hr; discontinue treatment when control achieved

Reassess diagnosis if no improvement within 2 weeks

Frequency Not Defined

Skin atrophy

Hypopigmentation

Miliaria

Cushing's syndrome

Dryness

Striae

Acneform lesions

Secondary infection

Irritation

HPA suppression (with higher potency used >2 wk)

Contraindications

Hypersensitivity

Underlying infection

Herpes simplex, varicella, vaccinia

Acne, rosacea, perioral dermatitis

Ophthalmic use

Cautions

Chronic topical corticosteroid therapy may interfere with growth and development in children

Pregnancy

Breastfeeding

Development of Kaposi's sarcoma with prolonged use reported (discontinue therapy if it occurs)

Use medium to very high potency for <2 wk to reduce local and systemic side effects

Use low potency for chronic therapy

Adrenal suppression may occur in younger patients or patients receiving high doses for prolonged periods

Avoid medium to very high potency on face, folds, groin because can increase steroid absorption

Use lower potency for peds (ie, increase BSA/kg, therefore increase systemic absorption)

Pregnancy & Lactation

Pregnancy Category: C

Lactation: It is not known whether topical administration of topical corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Use with caution.

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Mechanism of Action

Corticosteroids decrease inflammation by stabilizing leukocyte lysosomal membranes, preventing release of destructive acid hydrolases from leukocytes; inhibiting macrophage accumulation in inflamed areas; reducing leukocyte adhesion to capillary endothelium; reducing capillary wall permeability and edema formation; decreasing complement components; antagonizing histamine activity and release of kinin from substrates; reducing fibroblast proliferation, collagen deposition, and subsequent scar tissue formation

Pharmacokinetics

Absorption: 3% absorbed systemically after 8 hr following skin application

Images

No images available for this drug.

Patient Handout

A Patient Handout is not currently available for this monograph.

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Create Your List of Plans

Adding plans allows you to:

View the formulary and any restrictions for each plan.
Manage and view all your plans together – even plans in different states.
Compare formulary status to other drugs in the same class.
Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

View explanations for tiers and restrictions

Tier	Description
1	This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2	This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC	NOT COVERED – Drugs that are not covered by the plan.

Code	Definition
PA	Prior Authorization Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL	Quantity Limits Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST	Step Therapy Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR	Other Restrictions Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.

Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.

[CLOSE WINDOW]